Peter Wijngaard insider trades: Hepion Pharmaceuticals (HEPA) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Peter reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 27, 2023 | HEPA | ↑ Buy | 5,000 | $3.07 | $15K | Direct | Nov 28, 2023 (1d) |
| Sep 19, 2023 | HEPA | ↑ Buy | 3,000 | $5.61 | $17K | Direct | Sep 20, 2023 (1d) |
| Feb 16, 2021 | HEPA | ↑ Buy | 10,000 | $2.20 | $22K | Direct | Feb 18, 2021 (2d) |
| Dec 18, 2020 | HEPA | ↑ Buy | 20,000 | $1.91 | $38K | Direct | Dec 21, 2020 (3d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other HEPA insiders
Open-market trades in the last 12 months
About Peter Wijngaard's insider trades
Peter Wijngaard is a director at Hepion Pharmaceuticals (HEPA). Since Dec 18, 2020, Peter has reported 4 open-market purchases worth $92K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (4 filings), shares returned to the company (1 filing), option exercises (1 filing), shares withheld for taxes (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every HEPA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.